Alumis' LUMUS trial misses main goals in lupus, but subgroup shows benefit
The Phase 2b study of envudeucitinib failed on its primary and secondary endpoints overall, though patients with high interferon signature responded well, and Alumis plans to pursue Phase 3.
SEC filing